NervGen Pharma Corp. Common stock
NASDAQ:NGEN · NASDAQ Capital Market
-$0.02 today
Vol 1.48M · Avg 0.65M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-1268.9%
avg -191.8%
ROIC
-719.6%
avg -146.8%
ROA
-190.1%
avg -110.7%
Analysis
ROA is currently the strongest return metric at -190.1% versus its period average of -110.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Randall E. Kaye | Chief Medical Advisor & Director | $229,194.00 | — | 64 | — | — |
Adam H. Rogers | President, CEO & Chairman | — | — | — | — | — |
Harold Martin Punnett | Co-Founder & Independent Director | — | — | — | — | — |
Christine McSherry | Senior Vice President of Patient Advocacy & Clinical Affairs | — | — | — | — | — |
Shamim Ruff | Chief Regulatory Affairs Officer | — | — | 66 | — | — |
Keith A. Vendola | Chief Financial Officer | — | — | 54 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
No competitor data available.
Who manages NGEN?
NervGen Pharma Corp. Common stock (NGEN) lists 6 active executives. The top listed executive is Adam H. Rogers, President, CEO & Chairman.
Are NGEN insiders buying or selling?
Recent insider activity shows net buying of $6.21M.
Explore More
Continue the stock analysis
Jump to another research area for this company.